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BACKGROUND: Vascular endothelial growth factor receptor-3 (VEGFR-3) signalling mediates lymphangiogenesis and lymphatic invasion;
however, the effect of VEGFR-3 inhibition on the lymph node (LN) metastasis remains unclear. The aim of this study is to clarify the
benefit of a VEGFR-3 inhibitor Ki23057 for LN metastasis.
METHODS: Ki23057 was administered orally to gastric cancer models created by orthotopic inoculation of diffuse-type gastric cancer
cells, OCUM-2MLN. The effects of Ki23057 on lymphatic vessel invasion, lymphatic vessel density, and VEGFR-3 phosphorylation
were examined by immunostaining or immunoblotting.
RESULTS: Ki23057 inhibited the autophosphorylation of VEGFR-3, with IC50 values of 4.3nM in the cell-free kinase assay. Murine gastric
cancer models created by the orthotopic inoculation of OCUM-2MLN cells showed the diffusely infiltrating growth and frequently
developed LN metastasis. The oral administration of Ki23057 significantly (Po0.01) reduced the size of orthotopic tumours and the
number of the metastatic LN in gastric cancer models. The degree of lymphatic invasion and lymphangiogenesis was significantly
(Po0.05) lower in the gastric tumours treated by Ki23057. Ki23057 inhibited the phosphorylation of VEGFR-3 of lymphatic
endothelial cells in gastric tumours.
CONCLUSION: The inhibition of lymphangiogenesis targeting VEGFR-3 phosphorylation is a therapeutic strategy for inhibiting LN
metastasis of diffuse-type gastric cancer.
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The metastatic spread of tumour cells is responsible for the
majority of cancer deaths. In most solid tumours (including gastric
cancer), the spread of cancer cells through the lymphatics to
regional lymph nodes (LN) is a frequent event in the initial process
of cancer dissemination (Stacker et al, 2002a) and is an important
prognostic indicator for patient outcome (Otsuji et al, 2004;
Kunisaki et al, 2005; Yashiro et al, 2005). Nodal metastasis is
considered to be dependent on the tumour-induced lymphangio-
genesis or the invasion of preexisting lymphatic vessels (Clarijs
et al, 2001). In experimental tumours, vascular endothelial growth
factor (VEGF)-C and VEGF-D expressions induce lymphangiogen-
esis and correlate with lymphatic invasion and nodal metastasis
(Amioka et al, 2002; Gombos et al, 2005; Shida et al, 2006). Of the
three VEGF receptors (VEGF-Rs), VEGFR-3 signalling mediates
lymphangiogenesis in tumours and appears to have a significant
role in tumour metastasis through the lymphatics (Juttner et al,
2006). The signal through VEGFR-3 and VEGF-C is essential for
the development of lymphatic vessels (Karkkainen et al, 2004).
Targeting tumour lymphangiogenesis is considered to be an
attractive strategy for the treatment of LN metastatic diseases
because tumour-associated lymphatics are a key component of
metastatic spread. However, the therapeutic strategy targeting
VEGF/VEGFR-3 signalling to inhibit LN metastasis has been rare.
Taken together, it remains unclear whether the inhibition of
lymphangiogenesis targeting VEGFR-3 is a realistic therapeutic
strategy for inhibiting tumour cell dissemination and the
formation of nodal metastasis.
Ki23057, a newly developed tyrosine kinase inhibitor, competes
with ATP for the binding site in the kinase and therefore blocks the
autophosphorylation of VEGFR-3 and fibroblast growth factor
receptor 2 (FGFR-2) (Shimizu et al, 2004; Nakamura et al, 2006).
The characteristic clinical features of diffuse-type gastric carcino-
ma (DGC), a diffusely infiltrating type of gastric carcinoma also
known as scirrhous gastric carcinoma, include a high frequency of
metastasis to the LNs (Hippo et al, 2001; Nakazawa et al, 2003) and
to the peritoneum (Yashiro et al, 1996; Takemura et al, 2004;
Tendo et al, 2005). Although we currently reported the effects of
Ki23057 on the peritoneal dissemination of DGC with an
amplification of the activated FGF-R2 (K-samII) gene (Shimizu
et al, 2004; Nakamura et al, 2006), no candidate agent as VEGFR-3
phosphorylation inhibitor has yet been proposed for the molecular
target therapy of LN metastasis. The molecular controls of
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ling system may be targets for novel therapeutics designed to
restrict LN metastasis. In this study, to examine the benefit of the
VEGFR-3 inhibitor for DGC with LN metastasis, we explored the
possibility of preventing metastasis using molecular target therapy
of Ki23057.
MATERIALS AND METHODS
Phosphorylation inhibitor
Small-synthetic molecules that interrupt proliferation-related
receptor tyrosine kinase (RTK) pathways, Ki23057 (Shimizu
et al, 2004), was used in this study. Ki23057 was dissolved in
distilled water, stored in a light-shielded container at 41C, and
used within 5 days. For in vivo experiments, the agent dissolved in
distilled water was orally administered. For in vitro experiments,
the diluted Ki23057 was mixed at various concentrations with
Dulbecco’s modified Eagle’s medium (DMEM; Nikken, Kyoto,
Japan).
Cell lines
The human gastric cancer cell line (OCUM-2MLN; Fujihara et al,
1998, 1999; Hippo et al, 2001) and the human umbilical vein
endothelial cells (HUVECs) were used. OCUM-2MLN cell line was
derived from DGC. OCUM-2MLN cells have a high LN metastatic
potential in nude mice, as previously reported (Fujihara et al,
1998). OCUM-2MLN cells were cultured in medium consisted of
DMEM with 10% heat-inactivated fetal bovine serum (FBS; Life
Technologies, Grand Island, NY, USA). Human umbilical vein
endothelial cells were purchased from Kurabo (Osaka, Japan) and
cultured in endothelial cell growth medium 2 (HuMedia-EB2,
Kurabo), which contains 2% FBS, EGF 10ngml
 1, hydrocortisone
1mgml
 1, gentamicin 50mgml
 1, amphotericin B 50ngml
 1, basic
FGF 5ngml
 1, and heparin 10mlml
 1.
Animal models
The effects of Ki23057 administration on LN metastasis was
examined using mouse models of DGC with LN metastases as
described previously (Fujihara et al, 1998). Briefly, under ether
anaesthesia, a median abdominal incision was made in 4-week-old
female BALB/c nude mice (Clea Japan, Shizuoka, Japan). The
stomach was exposed carefully and OCUM-2MLN cells (5 10
6
cells per 100ml of DMEM) were inoculated orthotopically at the
stomach wall of the antrum using 30-G needles (Handaya, Saitama,
Japan). Beginning 7 days after tumour inoculation, medication was
administered orally five times weekly for 2 weeks. As the
elimination half-life (t1/2) of Ki23057 is 93h on oral administration
(Shimizu et al, 2004), orally five times weekly administration of
Ki23057 contribute to efficacy. The mice were killed 3 weeks after
tumour inoculation; gastric tumour size and total number and
weight of metastatic LNs in tumours resected from Ki23057-treated
animals (25mgkg
 1day
 1; n¼8) were compared with those in
tumours resected from vehicle control animals (n¼8). All
experiments with nude mice were performed in accordance with
the guidelines approved by the United Kingdom Coordinating
Committee on Cancer Research (1998).
Immunohistochemical techniques
Hematoxylin and eosin staining, Masson trichrome staining, and
the immunohistochemical determination of lymphatic vessel
endothelial hyaluronan receptor-1 (LYVE-1), CD31, VEGF-C, and
phosphorylation of VEGFR-3 were examined using orthotopic
tumours between the control and Ki23057-treated mice. Briefly,
paraffin-embedded sections were cut at 5mm. After the
deparaffinization and heating in Target Retrieval Solution (Dako,
Carpinteria, CA, USA), the sections were incubated with LYVE-1
(2 mgm l
 1; cat no. 103-PA50AG) (RELIATech, Braunschweig,
Germany), anti-CD31 antibody (sc-1506; Santa Cruz Biotechnology,
Santa Cruz, CA, USA), anti-VEGF-C antibody (Zymed, South
San Francisco, CA, USA), anti-Flt-4 antibody (BD Pharmingen,
San Diego, CA, USA), or phosphotyrosine (Zymed), and were
treated with a secondary antibody.
Quantitative analysis of lymphatic vessel and microvessel
Lymphatic vessel invasion (LVI) and lymphatic vessel density
(LVD) were determined by the hotspot method as previously
described (Gombos et al, 2005). Briefly, slides were scanned at low
power, and intratumoural and peri-tumoural areas with the
highest density of LYVE-1-positive vessels were identified.
Lymphatic vessel endothelial hyaluronan receptor-1 is used to
evaluate intratumoural lymphatic vessels in solid tumours.
Lymphatic vessel invasion or LVD was determined by counting
the number of LYVE-1-positive vessels with or without cancer
emboli in four high-power fields ( 100) in areas of the highest
lymphatic vessel as ‘hot spots’. Microvessel densities (MVDs)
were evaluated using immunohistochemical detection of CD31.
Four fields per tumour were scored for tumour microvessel
elements at  200 magnification, and the number of microvessel
elements per field was calculated as MVD. Areas of necrosis were
avoided.
Cellular and cell-free kinase assays
The proliferation of HUVECs in the presence and absence of VEGF
was evaluated using WST-8 colorimetric assay. Human umbilical
vein endothelial cells were seeded at 2 10
3 cells per well on a
96-well plate in the HuMedia-EB2 medium. Each well was treated with
Ki23057 at various concentrations (0, 10, 30, 100, and 300ngml
 1).
VEGF (10ngml
 1) was subsequently added to each well and the
plate was incubated for 72h. The live cell count was assayed using
Cell Counting Kit-8 (Dojin Laboratories, Kumamoto, Japan)
according to the instructions provided by the manufacturer, and
the absorbance of each well was measured at a test wavelength
of 450nm and a reference wavelength of 630nm with a microtiter
plate reader. Six replicate wells were used for each drug
concentration, and the testing was carried out independently for
thrice.
The ability of Ki23057 to inhibit VEGFR-3 phosphorylation was
evaluated using HUVECs that express the RTK of VEGFR-3,
as follows. Cells were harvested and plated onto the collagen
I-coated dishes and serum-starved in EBM-2 supplemented
0.5% FBS for 16h. After the addition of Ki23057, cells were
incubated for 1h and then stimulated with 100ngml
 1 recombi-
nant rat VEGF-C (RELIATech GmbH, Braunschweig, Germany) for
20min at 371C. After cell lysis, VEGFR-3 was immunoprecipitated
with anti-Flt-4 antibodies (Santa Cruz Biotechnology) and
subjected to immunoblotting with phosphotyrosine (Nakamura
et al, 2004).
The amount of phosphorylated and total protein for VEGFR-3 in
gastric tumour tissue was determined as follows. Briefly, tumour-
bearing mice were treated with either a vehicle control or Ki23057.
The mice were killed at 3 weeks after orthotopic inoculation.
Resected orthotopic tumours were snap-frozen on dry ice and
lysed in lysis buffer. The anti-Flt-4 antibodies react with mouse
VEGFR-3 (BD Pharmingen, San Diego, CA, USA), and were
immunoprecipitated and subjected to immunoblotting with
phosphotyrosine (Zymed). The extent of phosphorylation in
orthotopic tumours resected from Ki23057-treated animals was
compared with that in tumours resected from vehicle control
animals.
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The quantitative ratios of different groups were compared using
Student’s t-test. A difference was considered significant when the
P-value was p0.05.
RESULTS
Effect of Ki23057 on the VEGFR-3 phosphorylation in vitro
In biochemical assays using HUVECs that express the RTK of
VEGFR-3, Ki23057 exhibited competitive inhibition against
VEGFR-3 with an IC50 kinase value of 4.3nM (Figure 1A).
Ki23057 inhibited the autophosphorylation of VEGFR-3 with IC50
values of 37nM in the cellular assay (Figure 1B).
Effect of Ki23057 administration on DGC with LN
metastasis in vivo
Macroscopic findings of gastric tumours by the orthotopic
inoculation of OCUM-2MLN cells showed the diffusely infiltrating
growth resulting in thickening of the gastric wall accompanied by
pyloric stenosis, which resembled human DGC. The involvement
of numerous LNs was detected around the stomach, which was
similar to the development of human DGC with LN metastasis
(Figure 2A, left panel). The area of the orthotopically transplanted
tumours in mice treated with 25mgkg
 1day
 1 of Ki23057
(Figure 2A, right panel) was less than that of the control. The
nodal metastases in Ki23057-treated mouse were fewer and
smaller, in comparison with the control. Development of a gastric
tumour was found in eight out of eight (100%) control mice,
whereas that was five out of eight (63%) Ki23057-treated mice.
Orthotopic tumours of OCUM-2MLN cells showed extensive
fibrosis with the occasional presence of poorly differentiated
adenocarcinoma cells that resembles the characteristic histological
findings of human DGC by H&E staining, in both the control and
Ki23057-treated mice (Figure 2B). Masson trichrome staining
showed blue-colored multiple fibrosis in the both orthotopic
tumours, whereas no fibrotic change was found among the two
groups (Figure 2B). The primary tumours in mice receiving
Ki23057 were significantly smaller than those in the control mice
(Figure 2C). The weight and the number of LN metastases in mice
receiving Ki23057 were significantly lower than those in the
control mice (Figure 2D and E). No mice died during the
observation period. Neither weight loss nor any skin abnormalities
were associated with the administration of Ki23057. We added
these comments to the results.
Effect of Ki23057 administration on LVD of DGC in vivo
Vessels with a lumen that stained with LYVE-1 antibody were
considered lymphatic vessels. Lymphatic vessel density was
determined by LYVE-1-positive vessels without cancer emboli.
Lymphatic vessel invasion was identified as the presence of cancer
emboli within the channels lined by LYVE-1-positive vessels. The
number of lymphatic vessels and lymphatic invasion was fewer in
mice treated by Ki23057, compared with the control. VEGF-C
expression was heterogeneous within the tumours; however, the
expression levels of VEGF-C were not different between the control
and Ki23057-treated mice (Figure 3A). In comparison with the
control tumours, LVD was significantly (P¼0.016) less in the
gastric tumours treated by Ki23057 (Figure 3B). The extent of LVI
was significantly (P¼0.022) less in the gastric tumours treated by
Ki23057 in comparison with that in the control (Figure 3C).
Effects of Ki23057 on the phosphorylation of VEGFR-3
in vivo
To assess phosphorylation in tumour cells, tumour-bearing mice
were treated with vehicle control or a single dose of Ki23057.
Figure 4A shows the inhibitory effect of Ki23057 on the
phosphorylation of gastric tumour specimens. VEGFR-3 phos-
phorylation was suppressed in the tumours of Ki23057-treated
mice (mouse 2 and mouse 4) in comparison with that in the vehicle
mice (mouse 1 and mouse 3). The tumours from the control mice
that received vehicle only showed the strong staining of
phosphotyrosine on the lymphatic endothelial cells of VEGFR-3
staining. In contrast, the tumours from mice that received Ki23057
showed weak staining of phosphotyrosine on the lymphatic
endothelium (Figure 4B).
DISCUSSION
A few gastric cancer models with LN metastasis have been reported
(Yamaguchi et al, 2000; Yonemura et al, 2000; Takemura et al,
2004). In this study, the in vivo gastric cancer model with OCUM-
2MLN cells showed extensive fibrosis with the occasional presence
of diffuse-type adenocarcinoma cells, resulting in thickening and
stiffening of the gastric wall. In addition, the orthotopically planted
OCUM-2MLN cells frequently invade into lymphatic vessels and
displayed frequent LN metastasis. These findings suggest that this
model resembled human DGC and was useful for the evaluation of
therapies for primary gastric tumour and LN metastasis.
The metastatic spread of tumour cells causes the vast majority of
cancer deaths. Clinical and pathological evidence indicated that the
metastatic spread of tumours through lymphatic vessels to local/
regional LNs is an early event in metastatic disease for many solid
human tumours (Stacker et al, 2002b). Lymph node metastasis is
an important prognostic indicator for patient with DGC (Otsuji
et al, 2004; Kunisaki et al, 2005). Tumour cells can escape from the
primary site by entering existing vessels or new vessels actively
recruited into the primary tumour (Stacker et al, 2002b). There-
fore, the VEGF-C/VEGFR-3 signalling system for lymphangiogen-
esis might constitute a potential new target for the development of
anti-cancer therapeutics (Stacker et al, 2002b). In this study, the
LN metastases in mice treated with Ki23057 were significantly
smaller and fewer in comparison with the metastases detected in
Ki23057 (nM)
VEGF-C
0
–
0
+
1
+
3
+
10
+
30
+
100
+
300
+
1000
+
p-VEGF-R3
HUVEC
0
ATP (10 M)
VEGF-R3
0
0.1
0.2
0.3
0.4
O
D
 
(
4
5
0
 
n
m
)
Ki23057 (nM)
–
0
+
1
+
3
+
10
+
30
+
100
+
300
+
1000
+
A
B
Figure 1 Effect of Ki23057 on VEGFR-3 phosphorylation. (A) The ability
of Ki23057 to inhibit VEGFR-3 phosphorylation was evaluated using human
umbilical vein endothelial cells (HUVECs) that express the RTK of VEGFR-3.
Ki23057 inhibited the tyrosine phosphorylation of VEGFR-3 with IC50
values of 4.3nM.( B) For cellular assay, HUVECs were incubated with serial
concentrations of Ki23057. Ki23057 inhibited the growth of HUVEC with
VEGFR-3 activated by VEGF-C. Ki23057 inhibited the autophosphorylation
of VEGFR-3 at a dose-dependent manner. IC50 kinase value was estimated
as 37nM.
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Figure 2 Effects of Ki23057 in diffuse-type gastric carcinoma with lymph node metastasis. (A) Macroscopic findings of gastric tumours with lymph node metastasis.
The orthotopic inoculation showed diffuse-type gastric tumours (arrowheads). The area of the orthotopically transplanted tumours in Ki23057-treated mouse (right
panel) was less than that of the control (left panel). Large LN metastases (arrows) in control mice were recognised around the primary gastric tumour. Lymph node
metastases in Ki23057-treated mice were fewer in number and smaller than in controls. No toxicity or body weight loss was observed in any of the groups. (B)H & E
staining and Masson trichrome staining. Orthotopic tumours of OCUM-2MLN cells showed extensive fibrosis with the occasional presence of poorly differentiated
adenocarcinoma cells that resembled DGC. Extensive stromal fibrosis was also found in OCUM-2MLN gastric tumours treated by Ki23057. No remarkable difference
was found in the histological findings of orthotopic carcinomas between the control and Ki23057-treated mice by H&E staining. (C) The mean areas of the
orthotopically transplanted tumours in the control and Ki23057-treated mice were 15 and 6mm
2, respectively. Primary gastric tumours in mice receiving Ki23057
(25mgkg
 1day
 1)w e r es i g n i f i c a n t l y( P¼0.008) smaller than those in controls. (D and E) The mean weights of metastatic LN in the control and Ki23057-treated mice
were 91 and 11mg, respectively. The mean number of metastatic LN in the control and Ki23057-treated mice were 7.8 and 1.5, respectively. Ki23057 significantly
decreased both the mean weight (Po0.0001) and the mean number (Po0.0001) of involved nodes.
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sthe controls. The LVD values in the gastric tumours were
examined using LYVE-1 staining. The degree of lymphatic
invasion and the number of lymphatic vessels were significantly
fewer in the tumours treated by Ki23057. VEGFR-3 signalling
mediates lymphangiogenesis in tumours and would have a
significant role in tumour metastasis through the lymphatics
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Figure 3 Immunohistochemical expression of LYVE-1 and VEGF-C in orthotopic tumours. (A) Orthotopically planted OCUM-2MLN cells frequently
invade into lymphatic vessels. The number of lymphatic vessels at the invasive edge of tumours was fewer in mice treated by Ki23057, compared with the
control. The number of lymphatic invasion was fewer in the gastric tumours treated by Ki23057, compared with the control. Lymphatic vessels located at the
invasive edge of tumours were often enlarged and dilated. Expression level of VEGF-C was not different between the two groups. The LYVE-1 antibody
stains lymphatic vessels (arrowheads) and highlights lymphatic invasion (arrows). Many lymphatic vessels were found at the invasive edge of tumours. The
LYVE-1 antibody-stained vessels devoid of red blood cells corresponded to lymph vessels, whereas blood vessels were not stained (asterisks). Single-stained
endothelial cells were excluded. (B) Lymphatic vessel density (LVD) was determined by LYVE-1-positive vessels without cancer emboli. Respective mean
LVD in control and Ki23057 mice respectively were 26.5 and 10.4. The mean LVD was significantly decreased by Ki23057. (C) Lymphatic vessel endothelial
hyaluronan receptor-1 immunostaining highlighted the presence of lymphatic invasion. Lymphatic vessel invasion was identified as the presence of cancer
emboli within the channels lined by LYVE-1-positive vessels. Respective mean LVI (lymphatic vessel invasion) in control and Ki23057 mice were 3.5 and 0.7.
The LVI was significantly decreased by Ki23057. Lymphatic vessel invasion or LVD was determined by counting the number of LYVE-1-positive vessels with
or without cancer emboli in four high-power fields ( 100) in areas of the highest lymphatic vessel as ‘hot spots’.
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s(Kitadai et al, 2005; Juttner et al, 2006). Ki23057 showed
considerable inhibitory activity against autophosphorylation of
VEGFR-3 in vitro and in vivo; the IC50 for VEGFR-3 is 4.3nM in
the cellular assay and 5.4nM in the cell-free kinase assay.
Immunohistochemical studies also showed that the oral adminis-
tration of Ki23057 showed the inhibitory effect of VEGFR-3
phosphorylation for the lymph endothelial cells in the tumours of
the mice. In contrast, the expression level of VEGF-C was not
affected by Ki23057. These findings suggest that Ki23057 is a
promising molecular targeting agent for LN metastasis working as
a VEGFR-3 inhibitor against lymphangiogenesis in DGC.
The VEGFR-3 signalling system might be one of attractive targets
for antilymphangiogenic therapeutics designed to restrict LN
metastasis.
It is still controversial whether nodal metastasis is dependent on
tumour-induced lymphangiogenesis or the invasion of preexisting
lymphatic vessels (Clarijs et al, 2001). Our findings suggest that LN
metastasis is dependent on tumour-induced lymphangiogenesis
and indicate that the inhibition of lymphangiogenesis targeting
VEGFR-3 is a realistic therapeutic strategy for inhibiting LN
metastasis. In contrast, immunohistochemical study by CD31
showed that Ki23057 treatment resulted in no inhibition of tumour
MVD, which indicated that Ki23057 did not affect angiogenesis
within the primary tumours of DGC. Diffuse-type gastric
carcinoma has been reported to show the hypo-vascularity and
low VEGF expression, and the vessel count was not correlated with
the presence of endothelial VEGFR-2 in DGC (Takahashi et al,
1996). These findings might explain the reason for the ineffective-
ness of Ki23057 on the tumour MVD by CD31 staining in the DGC
tumour vasculature.
The oral administration of Ki23057 resulted in a reduction of the
gastric tumour size. We have previously reported that proliferation
of DGC cells was stimulated by FGF-7, which is a ligand of
FGFR-2, but not by VEGF. Ki23057 blocks the autophosphoryla-
tion of fibroblast growth factor receptor 2 and VEGFR-3 (Shimizu
et al, 2004; Nakamura et al, 2006). Ki23057 might decrease the
growth of DGC tumour by inhibiting the FGFR-2 signalling
pathway.
In conclusion, the inhibition of lymphangiogenesis targeting
VEGFR-3 is a realistic therapeutic strategy for inhibiting LN
metastasis. The autophosphorylation inhibitor against VEGFR-3,
Ki23057, might therefore be useful for the treatment of LN
metastasis of DGC.
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Figure 4 Inhibitory effect of Ki23057 on VEGFR-3 phosphorylation. (A) The inhibitory effect of Ki23057 on the phosphorylation of VEGFR-3 in gastric
tumour specimens. VEGFR-3 phosphorylation was suppressed in the tumours of the Ki23057-treated mice (mouse 2 and mouse 4), in comparison with that
in the vehicle mice (mouse 1 and mouse 3). (B) The effects of Ki23057 on VEGFR-3 phosphorylation levels on lymphatic endothelial cells. To assess the
phosphorylation of VEGFR-3 in tumour tissue, the anti-Flt-4 antibody reacts with mouse VEGFR-3 and phosphotyrosine was examined. Tumours treated by
Ki23057 showed an apparent attenuation of phosphorylation (arrows) on the lymphatic endothelial cells of VEGFR-3 staining (arrowheads), in comparison
with that in vehicle mice.
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